From Pilot to Precedent: How FDA’s Nicotine Pouch Program May Reshape Premarket Review
Inspired by analysis from Andrew Mooney of Broughton Group and broader discussions emerging from ATNF 2026. The U.S. Food and Drug Administration’s recent nicotine pouch pilot program may prove to be one of the most consequential regulatory developments for reduced-risk nicotine products in years, not because it lowered standards, but because it demonstrated that speed…